PER-069-09已完成未知
A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin
sanofi-aventis Recherche & Development,0 个研究点目标入组 0 人开始时间: 2009年11月11日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 50（—）
入选标准
- •Patients with type 2 diabetes mellitus, as defined by WHO, diagnosed for at least 1 year at the time of the screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 g/day for at least 3 months prior to the screening visit.
- •Patients with obesity (BMI = 30kg/m2) and aged from 18 years to less than 50 years.
- •Written informed consent obtained
排除标准
- •HbA1c < 7.0% or HbA1c >10% at screening
- •Type 1 diabetes mellitus
- •Pregnancy or lactation
- •Women of childbearing potential with no effective contraceptive method. Women of childbearing potential (pre-menopausal, not surgically sterile women for at least 3 months prior to the time of screening) must have a confirmed negative serum pregnancy test at screening visit.
- •Fasting Plasma Glucose at screening > 250 mg/dL (> 13.9 mmol/L)
- •Weight change of more than 5 kg during the 3 months preceding the screening visit
- •History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease, personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g multiple endocrine neoplasia syndromes),
- •History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening
- •Hemoglobinopathy or hemolytic anemia or receipt of blood or plasma products within 3 months prior to the time of screening
- •Within the last 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization
- •Known history of drug or alcohol abuse within 6 months prior to the time of screening
- •Any clinically significant abnormality identified on physical examination, laboratory tests, ECG or vital signs at the time of screening that in the judgment of the investigator or any sub investigator would preclude safe completion of the study or constrains efficacy assessment such as major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period.
- •Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure > 180 mmHg or > 110 mmHg, respectively
- •Laboratory findings at the time of screening: - Amylase and/or lipase > 3 times the upper limit of the normal laboratory range - ALT > 3 ULN - Total bilirubin: > 1.5 times the upper limit of the normal laboratory range (except in case of Gilbert’s syndrome) - Hemoglobin < 11 g/dL and/or neutrophils < 1,500/mm3 and/or platelets < 100,000/mm3 - Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody - Positive serum pregnancy test in females of childbearing potential - Calcitonin =20pg/mL (5.9 pml/L)
- •Patients considered by the investigator or any sub investigator as inappropriate for this study for any reason (e.g. impossibility to meet specific protocol requirements, such as scheduled visits, being able to do self-injections, likelihood of requiring treatment during the screening phase and treatment phase with drugs not permitted by the clinical study protocol, investigator or any sub investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol, etc)
- •Use of other oral or injectable antidiabetic or hypoglycemic agents other than metformin (e.g., sulfonylurea, alpha glucosidase inhibitor, thiazolidinedione, exenatide, DPP-4 inhibitors, insulin etc.) within 3 months prior to the time of screening
- •History of bariatric surgery, anti-obesity treatment or unstable diet within 3 months prior to the time of screening.
- •Use of systemic glucocorticoids (excluding topical application or inhaled forms) for one week or more within 3 month
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, 2-arm parallel-group, multicenter 24-week study comparing the efficacy and safety of AVE0010 to sitagliptin as add-on to metformin in obese type 2 diabetic patients younger than 50 and not adequately controlled with metformin.Type II DiabetesMedDRA version: 11.1Level: LLTClassification code 10045242Term: <Manually entered code. Term in E.1.1>EUCTR2008-007334-22-DESanofi-Aventis Recherche & Développement300
已完成
3 期
A clinical trial to study the effects of two drugs, Dynapar QPS and placebo topical solution in patient suffering from osteoarthritis.CTRI/2015/02/005510Troikaa Pharmaceuticals Limited212
已完成
2 期
To evaluate efficacy, safety and tolerability of two dose strengths of tacrolimus lipid suspension for injection rectally administered in adult patients with ulcerative colitisCTRI/2015/10/006252Intas Pharmaceuticals Ltd60
已完成
Unknown
A study to evaluate the safety and efficacy of a test product in female subjects with varied skin type.CTRI/2023/10/059282DPKA Universal Consumer Ventures Private Limited96
已完成
3 期
Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically IllCTRI/2020/05/025271Cadila Pharmaceuticals Limited481